AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Immunoglobulin Market: Opportunity Analysis and Industry Forecast, 2018 - 2025 - ResearchAndMarkets.com

December 2, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Dec 2, 2019--

The “Immunoglobulin Market by Application, Product Type, and by Mode of Delivery: Global Opportunity Analysis and Industry Forecast, 2018 - 2025” report has been added to ResearchAndMarkets.com’s offering.

Immunoglobulin Market Overview:

The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.

Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.

On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.

The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Immunoglobulin Market:

The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.

A comprehensive analysis of the factors that drive and restrict the market growth is provided.

A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.

Key players and their strategies are provided to understand the competitive outlook of the industry.

Key Topics Covered:

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

Chapter 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top Winning Strategies

3.3. Porters five forces analysis

3.4. Market share analysis, 2017

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in prevalence of immunodeficiency diseases

3.5.1.2. Increase in adoption of immunoglobulin

3.5.1.3. Increase in incidence of bleeding disorders

3.5.1.4. Surge in geriatric population

3.5.2. Restraints

3.5.2.1. Stringent government regulations

3.5.2.2. High cost of therapy

3.5.3. Opportunities

3.5.3.1. Opportunities in emerging economies

3.5.3.2. Development of cost-effective therapeutics through large-scale production

Chapter 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypogammaglobulinemia

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.4. Idiopathic thrombocytopenic purpura

4.5. Myasthenia Gravis

4.6. Multifocal Motor Neuropathy

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.8. Inflammatory Myopathies

4.9. Specific antibody deficiency

4.10. Guillain-Barre syndrome

4.11. Others

Chapter 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG

5.1.2. Key market trends

5.1.3. Clinical interpretations

5.1.4. IGA

5.1.7. IGM

5.1.10. IGE

5.1.13. IGD

Chapter 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

6.1. Overview

6.1.1. Market size and forecast

6.2. Intravenous Mode Of Delivery

6.2.1. Key Market Trends

6.2.2. Market size and forecast

6.2.2.1. 5% concentration

6.2.3. Market size and forecast

6.2.3.1. 10% Concentration

6.2.4. Market size and forecast

6.2.4.1. Other Concentrations

6.2.5. Market size and forecast

6.3. Subcutaneous Mode Of Delivery

6.3.1. Key Market Trends

6.3.2. Market size and forecast

6.3.2.1. 5% Concentration

6.3.3. Market size and forecast

6.3.3.1. 16.5% Concentration

6.3.4. Market size and forecast

6.3.4.1. 20% Concentration

6.3.5. Market size and forecast

6.3.5.1. Other Concentration

6.3.6. Market size and forecast

Chapter 7: IMMUNOGLOBULIN MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. North America market size & forecast, by country

7.2.3. North America market size & forecast, by application

7.2.4. North America market size & forecast, by mode of delivery

7.2.4.1. U.S. market size & forecast

7.2.4.2. Canada market size & forecast

7.2.4.3. Mexico market size & forecast

7.3. Europe

7.4. Asia-Pacific

7.5. LAMEA

Chapter 8: COMPANY PROFILES

8.1. Baxter International Inc.

8.1.1. Company overview

8.1.2. Company snapshot

8.1.3. Operating business segments

8.1.4. Product portfolio

8.1.5. Business performance

8.1.6. Key strategic moves and developments

8.2. BIoTest AG

8.3. CSL Limited

8.4. Grifols S.A.

8.5. LFB SA (LFB BIoTechnologies SAS)

8.6. Octapharma AG

8.7. Bayer AG

8.8. Kedrion Biopharma Inc.

8.9. Shire Plc.(Baxalta)

8.10. China Biologic Products, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/6iudmq

View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005371/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/02/2019 04:43 AM/DISC: 12/02/2019 04:43 AM

http://www.businesswire.com/news/home/20191202005371/en